80%Confidence
0Views
FDASource
2026-05-26Date
Summary
Endo USA's recall of buprenorphine injection due to particulate matter raises quality control concerns, potentially impacting hospital and clinic purchasing decisions. This could pressure Endo's revenue from this product line and invite regulatory scrutiny.
Actionable: Assess Endo's overall quality management and consider hedging against potential revenue loss from this product.
AI Confidence: 80%
Data Points
firmENDO USA, Inc.
classificationClass II
statusOngoing
distributionUSA Nationwide
productBuprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: Endo USA, Malvern, PA 19855, NDC 42023-179-05.
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now